BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
Commentary|Articles|June 30, 2026
Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?
Author(s)Joseph F. Goldberg, MD, Roy Perlis, MD
AI may assist psychopharmacology by aiding suicide risk, digital phenotyping, and TRD care—while exposing EHR data limits and the need for smarter integration.
Advertisement
Advertisement
BRAIN TRUST: CONVERSATIONS IN PSYCHOPHARMACOLOGY
Related to this article
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
Advertisement
Advertisement